17:22 , Apr 19, 2019 |  BC Week In Review  |  Company News

FDA approves Ibrance for men with breast cancer

Pfizer said FDA approved an sNDA for Ibrance palbociclib based on real-world data to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in men in combination with an aromatase inhibitor or fulvestrant. Pfizer Inc....
23:51 , Feb 21, 2019 |  BC Week In Review  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
21:30 , Feb 19, 2019 |  BC Extra  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
00:48 , Feb 1, 2019 |  BC Week In Review  |  Company News

Pfizer launches China's first pay-for-performance model for cancer

Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China on Jan 23. The program is the nation's first pay-for-performance insurance for oncology and covers 34 Chinese cities,...
22:16 , Jan 25, 2019 |  BC Extra  |  Company News

Pfizer launches China's first pay-for-performance model for cancer

Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is the nation's first pay-for-performance insurance for oncology and covers 34 Chinese cities, according to state-run...
19:29 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

G1's trilaciclib leads to PFS of up to 8.8 months in Phase II for TNBC

G1 Therapeutics Inc. (NASDAQ:GTHX) said trilaciclib (G1T28) administered on the day of chemotherapy led to a preliminary median progression-free survival (PFS) of 8.8 months vs. 5.4 months for chemotherapy alone in a Phase II trial...
18:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Nov. 27 after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:26 , Nov 27, 2018 |  BC Extra  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Tuesday after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate (ORR)...
16:57 , Oct 26, 2018 |  BC Week In Review  |  Company News

NICE recommends against abemaciclib for untreated breast cancer

The U.K.'s NICE issued draft guidance recommending against the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer. NICE said...